Skip to main content
SpringerLink
Log in
Book cover

Management of Soft Tissue Sarcoma pp 37–64Cite as

General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy

  • Chapter
  • First Online:

Abstract

The principal management of primary soft tissue sarcoma is surgical resection. The clinical goal is resection with negative margins, preferably that extend 2 cm from the grossly determined border. This can be difficult to assess and is often limited by the presence of major neurovascular and bony structures. The majority of soft tissue sarcomas do not invade into bone unless there has been previous injury to bone or the lesion has an epitheloid component, such as synovial sarcoma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Suzman MS, Smith AJ, Brennan MF. Fascio-peritoneal patch repair of the IVC: a workhorse in search of work? J Am Coll Surg. 2000;191(2):218–20.

    Article  PubMed  CAS  Google Scholar 

  2. Hollenbeck ST, Grobmyer SR, Kent KC, et al. Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg. 2003;197(4):575–9.

    Article  PubMed  Google Scholar 

  3. Russo P, Kim Y, Ravindran S, et al. Nephrectomy during operative management of retroperitoneal sarcoma. Ann Surg Oncol. 1997;4(5):421–4.

    Article  PubMed  CAS  Google Scholar 

  4. Brennan MF, Lewis JJ. Diagnosis and management of soft tissue sarcoma. London: Martin Dunitz Ltd; 2002.

    Google Scholar 

  5. Eilber FC, Brennan MF, Riedel E, et al. Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas. Ann Surg Oncol. 2005;12(3):228–36.

    Article  PubMed  Google Scholar 

  6. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology. 1997;202(1):237–46.

    PubMed  CAS  Google Scholar 

  7. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009;361(9):849–57.

    Article  PubMed  CAS  Google Scholar 

  8. Benz MR, Dry SM, Eilber FC, et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010;51(8):1174–81.

    Article  PubMed  Google Scholar 

  9. Eary JF, Conrad EU. PET imaging: update on sarcomas. Oncology (Williston Park). 2007;21(2):249–52.

    Google Scholar 

  10. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol. 2006;18(4):369–73.

    Article  PubMed  Google Scholar 

  11. Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218(6):705–12.

    Article  PubMed  CAS  Google Scholar 

  12. Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary metastasis: a 20-year experience. Ann Thorac Surg. 1984;38(4):323–30.

    Article  PubMed  CAS  Google Scholar 

  13. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229(5):602–10. discussion 610–602.

    Article  PubMed  CAS  Google Scholar 

  14. Weiser MR, Downey RJ, Leung DH, et al. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg. 2000;191(2):184–90. discussion 190–181.

    Article  PubMed  CAS  Google Scholar 

  15. Temple LK, Brennan MF. The role of pulmonary metastasectomy in soft tissue sarcoma. Semin Thorac Cardiovasc Surg. 2002;14(1):35–44.

    Article  PubMed  Google Scholar 

  16. Canter RJ, Qin LX, Downey RJ, et al. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: a retrospective analysis. Cancer. 2007;110(9):2050–60.

    Article  PubMed  Google Scholar 

  17. DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001;234(4):540–7. discussion 547–548.

    Article  PubMed  CAS  Google Scholar 

  18. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14(3):859–68.

    PubMed  CAS  Google Scholar 

  19. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.

    PubMed  CAS  Google Scholar 

  20. O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.

    Article  PubMed  Google Scholar 

  21. Alektiar KM, Hong L, Brennan MF, et al. Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. Int J Radiat Oncol Biol Phys. 2007;68(2):458–64.

    Article  PubMed  Google Scholar 

  22. Alektiar KM, Brennan MF, Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. Cancer. 2011;117(14):3229–34.

    Article  PubMed  Google Scholar 

  23. Davis AM, O’Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53.

    Article  PubMed  Google Scholar 

  24. Ormsby MV, Hilaris BS, Nori D, et al. Wound complications of adjuvant radiation therapy in patients with soft-tissue sarcomas. Ann Surg. 1989;210(1):93–9.

    Article  PubMed  CAS  Google Scholar 

  25. Arbeit JM, Hilaris BS, Brennan MF. Wound complications in the multimodality treatment of extremity and superficial truncal sarcomas. J Clin Oncol. 1987;5(3):480–8.

    PubMed  CAS  Google Scholar 

  26. Alekhteyar KM, Leung DH, Brennan MF, et al. The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin. Int J Radiat Oncol Biol Phys. 1996;36(2):321–4.

    Article  PubMed  CAS  Google Scholar 

  27. Alektiar KM, Velasco J, Zelefsky MJ, et al. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2000;48(4):1051–8.

    Article  PubMed  CAS  Google Scholar 

  28. Kepka L, DeLaney TF, Suit HD, et al. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005;63(3):852–9.

    Article  PubMed  Google Scholar 

  29. Zelefsky MJ, Nori D, Shiu MH, et al. Limb salvage in soft tissue sarcomas involving neurovascular structures using combined surgical resection and brachytherapy. Int J Radiat Oncol Biol Phys. 1990;19(4):913–8.

    Article  PubMed  CAS  Google Scholar 

  30. Shiu MH, Collin C, Hilaris BS, et al. Limb preservation and tumor control in the treatment of popliteal and antecubital soft tissue sarcomas. Cancer. 1986;57(8):1632–9.

    Article  PubMed  CAS  Google Scholar 

  31. Alektiar KM, Zelefsky MJ, Brennan MF. Morbidity of adjuvant brachytherapy in soft tissue sarcoma of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys. 2000;47(5):1273–9.

    Article  PubMed  CAS  Google Scholar 

  32. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350(9092):1647–54.

    Article  Google Scholar 

  33. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3(9):1240–5.

    PubMed  CAS  Google Scholar 

  34. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009;112(3):563–7.

    Article  PubMed  CAS  Google Scholar 

  35. Clinicaltrials.gov. Study NCT00282087 (2009). Accessed 15 July 2009.

    Google Scholar 

  36. Alvegard TA, Sigurdsson H, Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma group. J Clin Oncol. 1989;7(10):1504–13.

    PubMed  CAS  Google Scholar 

  37. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma–reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137–49.

    PubMed  CAS  Google Scholar 

  38. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.

    PubMed  CAS  Google Scholar 

  39. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.

    Article  PubMed  CAS  Google Scholar 

  40. Brodowicz T, Schwameis E, Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 2000;4(4):151–60.

    Article  PubMed  CAS  Google Scholar 

  41. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. J Clin Oncol (Meeting Abstr). 2007;25 Suppl 18:10008.

    Google Scholar 

  42. Collaboration SM-A. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350(9092):1647–54.

    Article  Google Scholar 

  43. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.

    Article  PubMed  Google Scholar 

  44. Toulmonde M, Bellera C, Mathoulin-Pelissier S, et al. Quality of randomized controlled trials reporting in the treatment of sarcomas. J Clin Oncol. 2011;29(9):1204–9.

    Article  PubMed  Google Scholar 

  45. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104.

    Article  PubMed  CAS  Google Scholar 

  46. Corless CL, Ballman KV, Antonescu C, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010;28 Suppl 15:10006.

    Google Scholar 

  47. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.

    Article  PubMed  CAS  Google Scholar 

  48. Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol. 2010;11(2):184–92.

    Article  PubMed  CAS  Google Scholar 

  49. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(15):2536–41.

    Article  PubMed  CAS  Google Scholar 

  50. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091–102.

    PubMed  CAS  Google Scholar 

  51. Antman K, Crowley J, Balcerzak SP, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma. Cancer. 1998;82(7):1288–95.

    Article  PubMed  CAS  Google Scholar 

  52. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 2003;98(9):1942–6.

    Article  PubMed  CAS  Google Scholar 

  53. del Garcia MX, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 2005;104(8):1706–12.

    Article  Google Scholar 

  54. Boyar MS, Hesdorffer M, Keohan ML, et al. Phase II Study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma. Sarcoma. 2008;2008:412503.

    Article  PubMed  Google Scholar 

  55. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11(3):241–7.

    Article  PubMed  Google Scholar 

  56. Penel N, Italiano A, Ray-Coquard I, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23(2):517–23.

    Article  PubMed  CAS  Google Scholar 

  57. Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118(13):3330–6.

    Google Scholar 

  58. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23(3):311–21.

    Article  PubMed  CAS  Google Scholar 

  59. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506–11.

    Article  PubMed  CAS  Google Scholar 

  60. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824–31.

    Article  PubMed  CAS  Google Scholar 

  61. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755–63.

    Article  PubMed  CAS  Google Scholar 

  62. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188–96.

    Article  PubMed  CAS  Google Scholar 

  63. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.

    Article  PubMed  Google Scholar 

  64. Mason M, Robinson M, Harmer C, et al. Intra-arterial adriamycin, conventionally fractionated radiotherapy and conservative surgery for soft tissue sarcomas. Clin Oncol (R Coll Radiol). 1992;4(1):32–5.

    Article  CAS  Google Scholar 

  65. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14(10):2653–65.

    PubMed  CAS  Google Scholar 

  66. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4(7):429–37.

    Article  PubMed  Google Scholar 

  67. Wiedemann GJ, D’Oleire F, Knop E, et al. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res. 1994;54(20):5346–50.

    PubMed  CAS  Google Scholar 

  68. Wendtner CM, Abdel-Rahman S, Krych M, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002;20(14):3156–64.

    Article  PubMed  CAS  Google Scholar 

  69. Issels RD, Abdel-Rahman S, Wendtner C, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer. 2001;37(13):1599–608.

    Article  PubMed  CAS  Google Scholar 

  70. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561–70.

    Article  PubMed  CAS  Google Scholar 

  71. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol. 2002;9(1):48–56.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Center & Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Murray F. Brennan

  2. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Cristina R. Antonescu

  3. Departments of Medicine Pediatrics, and Orthopaedics, Mount Sinai School of Medicine, New York, NY, USA

    Robert G. Maki

Authors
  1. Murray F. Brennan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina R. Antonescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert G. Maki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brennan, M.F., Antonescu, C.R., Maki, R.G. (2013). General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy. In: Management of Soft Tissue Sarcoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5004-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5004-7_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5003-0

  • Online ISBN: 978-1-4614-5004-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation